The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy

Grazyna Adamus, Nata Aptsiauri, John Guy, John Heckenlively, John Flannery, Paul A. Hargrave

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Cancer-associated retinopathy (CAR) is an uncommon paraneoplastic disease in which degeneration of the retina occurs as a remote effect of cancer in a distant part of the body. Immunoreactivity of sera from CAR patients and controls have been analyzed. Immunostaining of human retinal proteins showed that a soluble protein of M(r) ~ 46 kDa (p46) is labeled by antibodies from several CAR patients with various types of cancer (lung, breast, bladder, prostate, salivary gland, and gastrointestinal tract cancer and chronic lymphocytic leukemia). These sera did not show reactivity with the 23-kDa protein previously associated with CAR. To identify and further characterize p46, the retinal protein was purified to homogeneity by anion-exchange chromatography and preparative gel electrophoresis. Protein sequence analysis of the peptides from p46 revealed a high homology with human enolase, an important glycolytic enzyme. Although enolase has been previously identified as a product of several types of tumors, and enolase activity has been detected in the sera of some cancer patients, the existence of autoantibodies directed to enolase has not been described. This is the first report of the presence of serum antibodies to retinal enolase in the patients with cancer and the CAR syndrome. When antibodies of specific isotypes (IgG, IgM, and IgA) were measured, IgG1 isotype was dominant. The significance of these antibodies for the disease process is under investigation.

Original languageEnglish
Pages (from-to)120-129
Number of pages10
JournalClinical Immunology and Immunopathology
Volume78
Issue number2
DOIs
StatePublished - Mar 19 1996
Externally publishedYes

Fingerprint

Ocular Paraneoplastic Syndromes
Phosphopyruvate Hydratase
Autoantibodies
Serum
Antibodies
Neoplasms
Proteins
Immunoglobulin G
Gastrointestinal Neoplasms
Protein Sequence Analysis
B-Cell Chronic Lymphocytic Leukemia
Salivary Glands
Human Body
Immunoglobulin A
Gel Chromatography
Anions
Immunoglobulin M
Electrophoresis
Retina
Prostate

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pathology and Forensic Medicine

Cite this

The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. / Adamus, Grazyna; Aptsiauri, Nata; Guy, John; Heckenlively, John; Flannery, John; Hargrave, Paul A.

In: Clinical Immunology and Immunopathology, Vol. 78, No. 2, 19.03.1996, p. 120-129.

Research output: Contribution to journalArticle

Adamus, Grazyna ; Aptsiauri, Nata ; Guy, John ; Heckenlively, John ; Flannery, John ; Hargrave, Paul A. / The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. In: Clinical Immunology and Immunopathology. 1996 ; Vol. 78, No. 2. pp. 120-129.
@article{3f37e6708ea24e8ea26f25c09dc692d1,
title = "The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy",
abstract = "Cancer-associated retinopathy (CAR) is an uncommon paraneoplastic disease in which degeneration of the retina occurs as a remote effect of cancer in a distant part of the body. Immunoreactivity of sera from CAR patients and controls have been analyzed. Immunostaining of human retinal proteins showed that a soluble protein of M(r) ~ 46 kDa (p46) is labeled by antibodies from several CAR patients with various types of cancer (lung, breast, bladder, prostate, salivary gland, and gastrointestinal tract cancer and chronic lymphocytic leukemia). These sera did not show reactivity with the 23-kDa protein previously associated with CAR. To identify and further characterize p46, the retinal protein was purified to homogeneity by anion-exchange chromatography and preparative gel electrophoresis. Protein sequence analysis of the peptides from p46 revealed a high homology with human enolase, an important glycolytic enzyme. Although enolase has been previously identified as a product of several types of tumors, and enolase activity has been detected in the sera of some cancer patients, the existence of autoantibodies directed to enolase has not been described. This is the first report of the presence of serum antibodies to retinal enolase in the patients with cancer and the CAR syndrome. When antibodies of specific isotypes (IgG, IgM, and IgA) were measured, IgG1 isotype was dominant. The significance of these antibodies for the disease process is under investigation.",
author = "Grazyna Adamus and Nata Aptsiauri and John Guy and John Heckenlively and John Flannery and Hargrave, {Paul A.}",
year = "1996",
month = "3",
day = "19",
doi = "10.1006/clin.1996.0021",
language = "English",
volume = "78",
pages = "120--129",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy

AU - Adamus, Grazyna

AU - Aptsiauri, Nata

AU - Guy, John

AU - Heckenlively, John

AU - Flannery, John

AU - Hargrave, Paul A.

PY - 1996/3/19

Y1 - 1996/3/19

N2 - Cancer-associated retinopathy (CAR) is an uncommon paraneoplastic disease in which degeneration of the retina occurs as a remote effect of cancer in a distant part of the body. Immunoreactivity of sera from CAR patients and controls have been analyzed. Immunostaining of human retinal proteins showed that a soluble protein of M(r) ~ 46 kDa (p46) is labeled by antibodies from several CAR patients with various types of cancer (lung, breast, bladder, prostate, salivary gland, and gastrointestinal tract cancer and chronic lymphocytic leukemia). These sera did not show reactivity with the 23-kDa protein previously associated with CAR. To identify and further characterize p46, the retinal protein was purified to homogeneity by anion-exchange chromatography and preparative gel electrophoresis. Protein sequence analysis of the peptides from p46 revealed a high homology with human enolase, an important glycolytic enzyme. Although enolase has been previously identified as a product of several types of tumors, and enolase activity has been detected in the sera of some cancer patients, the existence of autoantibodies directed to enolase has not been described. This is the first report of the presence of serum antibodies to retinal enolase in the patients with cancer and the CAR syndrome. When antibodies of specific isotypes (IgG, IgM, and IgA) were measured, IgG1 isotype was dominant. The significance of these antibodies for the disease process is under investigation.

AB - Cancer-associated retinopathy (CAR) is an uncommon paraneoplastic disease in which degeneration of the retina occurs as a remote effect of cancer in a distant part of the body. Immunoreactivity of sera from CAR patients and controls have been analyzed. Immunostaining of human retinal proteins showed that a soluble protein of M(r) ~ 46 kDa (p46) is labeled by antibodies from several CAR patients with various types of cancer (lung, breast, bladder, prostate, salivary gland, and gastrointestinal tract cancer and chronic lymphocytic leukemia). These sera did not show reactivity with the 23-kDa protein previously associated with CAR. To identify and further characterize p46, the retinal protein was purified to homogeneity by anion-exchange chromatography and preparative gel electrophoresis. Protein sequence analysis of the peptides from p46 revealed a high homology with human enolase, an important glycolytic enzyme. Although enolase has been previously identified as a product of several types of tumors, and enolase activity has been detected in the sera of some cancer patients, the existence of autoantibodies directed to enolase has not been described. This is the first report of the presence of serum antibodies to retinal enolase in the patients with cancer and the CAR syndrome. When antibodies of specific isotypes (IgG, IgM, and IgA) were measured, IgG1 isotype was dominant. The significance of these antibodies for the disease process is under investigation.

UR - http://www.scopus.com/inward/record.url?scp=0029916703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029916703&partnerID=8YFLogxK

U2 - 10.1006/clin.1996.0021

DO - 10.1006/clin.1996.0021

M3 - Article

C2 - 8625554

AN - SCOPUS:0029916703

VL - 78

SP - 120

EP - 129

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -